Review
doi: 10.3109/10826088509047756.
Pharmacological advances in addiction treatment
- PMID: 2867050
- DOI: 10.3109/10826088509047756
Item in Clipboard
Review
Pharmacological advances in addiction treatment
Int J Addict.
1985 Jun-Jul.
Abstract
In the past 20 years significant advances in the pharmacological treatment of opioid dependence have been made, and research in this area is continuing. Therapeutic applications and current research in the use of pharmacological agents in maintenance therapy, treatment with narcotic antagonists, and narcotic detoxification are discussed. In addition, an overview is presented of recent developments in opioid pharmacology and of recently developed novel pharmacological agents which may prove useful in the future treatment and/or prevention of opioid dependence.
Similar articles
-
Clinical treatment of opioid addiction and dependence.Methods Mol Med. 2003;84:285-95. doi: 10.1385/1-59259-379-8:285. Methods Mol Med. 2003. PMID: 12703332 No abstract available.
-
Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.J Addict Dis. 2001;20(4):1-5. doi: 10.1300/J069v20n04_01. J Addict Dis. 2001. PMID: 11760922 No abstract available.
-
Expanded table: Some drugs for management of opioid withdrawal symptoms.Med Lett Drugs Ther. 2018 Aug 27;60(1554):e144-e146. Med Lett Drugs Ther. 2018. PMID: 30133422 No abstract available.
-
Pharmacologic treatments for heroin and cocaine dependence.Am J Addict. 2003;12(s2):S5-S18. Am J Addict. 2003. PMID: 12857659 Review.
-
The sequential use of clonidine and naltrexone in the treatment of opiate addicts.Adv Alcohol Subst Abuse. 1984 Spring;3(3):19-39. doi: 10.1300/J251v03n03_03. Adv Alcohol Subst Abuse. 1984. PMID: 6388273 Review.
Cited by
-
Alpha₂-adrenergic agonists for the management of opioid withdrawal.Cochrane Database Syst Rev. 2016 May 3;2016(5):CD002024. doi: 10.1002/14651858.CD002024.pub5. Cochrane Database Syst Rev. 2016. PMID: 27140827 Free PMC article.
-
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.Drugs. 1988 Mar;35(3):192-213. doi: 10.2165/00003495-198835030-00002. Drugs. 1988. PMID: 2836152 Review.
-
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.Drug Alcohol Depend. 2008 Sep 1;97(1-2):158-68. doi: 10.1016/j.drugalcdep.2008.04.002. Epub 2008 May 27. Drug Alcohol Depend. 2008. PMID: 18508207 Free PMC article. Clinical Trial.
-
Clinical consequences of abrupt drug withdrawal.Med Toxicol Adverse Drug Exp. 1987 Sep-Oct;2(5):367-82. doi: 10.1007/BF03259954. Med Toxicol Adverse Drug Exp. 1987. PMID: 3312931 Review.
-
Opioid antagonists with minimal sedation for opioid withdrawal.Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4. Cochrane Database Syst Rev. 2017. PMID: 28553701 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
etc
LinkOut - more resources
Medical
Miscellaneous